Company Aggregate Debt: tempesttx.com (TPST)

Tempest Therapeutics (TPST) is seeking alliances with industry behemoths to fund final drug trials. Patent protection for small molecules ensures long-term revenue, as evidenced by the change in debt volume, where the indicator settled at 0.00. High margins on global sales coupled with low costs make this biotech model a benchmark for scalability.

For Tempest Therapeutics (TPST), which has no commercial products, the total debt burden reflects a critical dependence on external financing during the clinical trial period. This metric aggregates all short-term and long-term liabilities, allowing investors to assess insolvency risk in the absence of operating revenue and determine the balance sheet's margin of safety before a potential default.